British-American surgeon, professor, author and medical commentator.
The UK has passed the Tobacco and Vapes Act, which has created a rolling age ban that will permanently prevent anyone born on or after 1 January 2009 from legally buying tobacco. The law has also granted ministers broad powers to regulate vaping — including flavours, packaging, displays and where vaping is allowed — and will tighten sales rules for under‑18s.
Multiple outlets have reported that President Trump has said he 'doesn't think about' Americans' financial situation while negotiating with Iran, insisting preventing Tehran from a nuclear weapon is his sole focus. The comment has come as inflation has accelerated to 3.8% and gasoline has jumped above $4.50 a gallon since the war with Iran began.
The Supreme Court has issued an emergency order keeping mifepristone available by mail and via telehealth while litigation continues. The action preserves access as lawsuits challenge FDA rules on prescribing the abortion pill, with a ruling likely not until next year.
The FDA has approved bemotrizinol (BEMT) for over‑the‑counter sunscreens, marking a modernization in U.S. UV protection. The ingredient absorbs both UVA and UVB rays, is photostable, and will debut as Parsol Shield before broader market adoption after an 18‑month exclusivity period. Industry and dermatology experts say the move could improve protection and user experience, though rollout and formulation timelines remain.
The FDA has approved bemotrizinol, a chemical UV filter used in European and Asian sunscreens for over 20 years. It offers UVA and UVB protection, is photostable, and may lead to more elegant, higher-SPF products in the US. The move comes after decades of FDA inaction on new filters, with products containing bemotrizinol expected to reach US shelves after about 18 months.
Reports show rising youth nicotine use and regulatory debates over fruit-flavored vapes. The FDA has approved some flavors for adults; critics warn this may attract teens. Experts urge stronger prevention and clearer guidance.
Pfizer has reported that its experimental drug sigvotatug vedotin did not improve survival in advanced non‑small cell lung cancer compared with standard therapy. The result setbacks expectations for a potential first‑in‑class antibody‑drug conjugate and follows Pfizer’s 2023 Seagen purchase.
A new weight‑loss pill version of semaglutide has launched in the UK for private prescriptions, offering an alternative to injections. The tablet requires strict dosing and a fasting routine and is not yet NHS‑funded. Several outlets warn about counterfeit pills as access broadens.
Eli Lilly has announced an all-cash deal to acquire AtaiBeckley for up to $2.8 billion upfront, with potential milestone payments. AtaiBeckley’s lead drug, a DMT-related nasal spray for treatment-resistant depression, is in Phase 3, with initial results expected in 2029. The deal signals growing pharma interest in psychedelic therapies amid regulatory momentum.
The FDA has approved Lipfendra, Merck’s oral PCSK9 inhibitor, to lower LDL cholesterol in patients on statins. Trials show ~55-60% LDL reductions; the pill will be sold at about $315/month and must be taken on an empty stomach. Analysts see potential peak sales in the billions as injectable rivals face competition and access barriers.
Moderna has secured FDA approval for mFlusiva in adults 50-64 with full approval and for 65+ with accelerated approval, based on a 40,000-person study showing reduced flu cases vs standard vaccines. Availability is rolling out ahead of fall, with postmarket studies planned to confirm benefits in seniors.